- Home
- PENG vs KALV Comparison
PENG vs KALV Comparison
Compare PENG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | KALV |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.9M | 757.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PENG | KALV |
|---|---|---|
| Price | $16.66 | $19.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $27.75 | ★ $32.60 |
| AVG Volume (30 Days) | 685.2K | ★ 931.8K |
| Earning Date | 04-01-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $8.85 | $122.34 |
| Revenue Next Year | $13.02 | $99.65 |
| P/E Ratio | $87.50 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $14.20 | $9.83 |
| 52 Week High | $29.80 | $19.27 |
Technical Indicators
Market Signals| Indicator | PENG | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 67.38 |
| Support Level | N/A | $14.66 |
| Resistance Level | $21.17 | N/A |
| Average True Range (ATR) | 0.65 | 1.25 |
| MACD | -0.05 | 0.20 |
| Stochastic Oscillator | 2.70 | 87.65 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.